QUEST is aligned with the 2025 Diabetes Canada Guidelines
QUEST makes it easy to see how your practice aligns with the updated Pharmacotherapy and CKD Guidelines
Guidelines Updates at a Glance
Cardiovascular Disease (CVD) & Diabetes
Updated guidelines place SGLT2 inhibitors and GLP-1 receptor agonists at the center of care for people with type 2 diabetes and cardiovascular risk — regardless of A1C level.
Use SGLT2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes and cardiovascular disease or multiple CV risk factors — even when A1C is at target.
Prefer SGLT2i (empagliflozin, canagliflozin, dapagliflozin) to reduce heart failure and kidney progression.
Prefer GLP-1RA (dulaglutide, liraglutide, injectable semaglutide) to reduce stroke risk.
Chronic Kidney Disease (CKD)
CKD management now emphasizes SGLT2 inhibitors as first choice, with safe initiation down to eGFR ≥20, and GLP-1RAs added when further glucose or weight control is needed.
Prioritize SGLT2 inhibitors for patients with diabetes and CKD.
Add a GLP-1RA if additional glucose or weight control is needed.
Safe to initiate SGLT2i if eGFR ≥20 mL/min/1.73 m².[HS1]
Kidney Function Testing
Guidelines reinforce early and ongoing kidney monitoring — with more frequent testing for those at higher risk.
At diagnosis: order eGFR + urine ACR to establish baseline.
Annually: repeat in all stable patients.
Every 3–6 months: if CKD, albuminuria, or declining eGFR.
New (2025): consider cystatin-C when creatinine-based eGFR is unreliable; use KFRE in advanced CKD (G3–G5) to stratify risk and guide referral.
What You Will Receive: The QUEST Report
A confidential, practice-level snapshot aligned with the 2025 Guideline updates.
Insights on patients with T2D who also have CVD, CKD, or may be missing recommended therapies or kidney function testing.
Clear direction on where your practice is aligned — and where quality improvement opportunities exist.
See an Example of the Report Below:
What our Leaders are Saying
-
"Our members see huge opportunity in QUEST. We’ve done our due diligence and know it will add real value for family physicians."
Jess Rogers | CEO, AFHTO
-
“When clinicians see their own data, it sparks change — not because someone told them to, but because they see it themselves.”
Ted Alexander | VP, Amplify Care
-
Quote
Quote source
Powered by Experts in Primary Care, Data, and Education
QUEST is a collaboration between organizations committed to streamlining traditional QI processes to remove barriers to participation.
Join QUEST Today
Register now to receive your personalized report.